Unregistered Sales of Equity Securities and Use of Proceeds
−Removed: UTMD did not purchase any of its own securities in 9M 2023.
−Removed: During 2Q 2022/ 9M 2022 UTMD purchased 30,105 of its shares in the open market for $2,495 including commissions and fees ($82.88/ share.)
+Added: The following table details purchases by UTMD of its own securities during 1Q 2024.
+Added: ISSUER PURCHASES OF EQUITY SECURITIES
+Added: Total number of shares purchased (1)
+Added: Average price paid per share (1)
+Added: Total number of shares purchased as part of publicly announced plans or programs (1)
+Added: Maximum number (or approximate dollar value) of shares that may yet be purchased under the plans or programs (1)
+Added: 01/01/24 – 01/31/24
+Added: 02/01/24 – 02/29/24
+Added: 03/01/24 – 03/31/24
+Added: 1) None of the shares were purchased as part of a publicly announced plan and all were purchased on the open market.
+Added: The frequency of UTMD’s open market share repurchases depends on the availability of sellers and the price of the stock.
+Added: The board of directors has not established an expiration date or a maximum dollar or share limit for UTMD’s continuing and long-term pattern of open market share repurchases since 1992.
+Added: The purpose of UTMD’s ongoing share repurchases is to maximize the value of the Company for its continuing stockholders, and maximize its return on stockholder equity by employing excess cash generated by effectively managing its business .
+Added: UTMD does not intend to repurchase shares that would result in terminating its Nasdaq Global Market listing.
+Added: Please see item 9) Subsequent Events in the Notes to Financial Statements for shares repurchased in April 2024.
Title of Document
6 unchanged sentences
The following financial information from the Utah Medical Products, Inc.
−Removed: quarterly report on Form 10-Q for the quarter ended September 30, 2023, formatted in Inline Extensible Business Reporting Language (iXBRL):
+Added: quarterly report on Form 10-Q for the quarter ended March 31, 2024, formatted in Inline Extensible Business Reporting Language (iXBRL):
(i) Consolidated Condensed Balance Sheets, (ii) Consolidated Condensed Statements of Income, (iii) Consolidated Condensed Statements of Cash Flows, (iv) Consolidated Condensed Statements of Stockholders’ Equity, and (v) related Notes to the Consolidated Condensed Financial Statements, tagged in detail.
4 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.